Jeremy Goldstein speaks of the implications of EPS in corporations.

Jeremy Goldstein speaks of the implications of EPS in corporations. Learn more: https://nycinquirer.com/2018/01/15/nyc-lawyer-jeremy-goldstein-recommends-compromise-for-employment-incentives/

 

A large number of factors influence a sustainable economic market for corporate organizations. These pose great challenges to the said corporations. Jeremy Goldstein is an attorney practicing in New York City. He has witnessed how the said challenges may cause adverse loses to investors and employees. His vast experience in the corporate sector enables him to offer up expert advice. He guides institutions on how to handle Earnings Per Share(EPS). He offers a new perception into the use of the EPS in pay programs that are based on performance.

 

Critics have termed the use of EPS as being partial to the executive parts of a corporation. They believe that rather than providing collective control, it gives excessive powers to CEOs. This in short means that the higher ups could be coming up with false data. This misrepresents a company’s performance hence illegally driving up its share sales. Some also offer that the EPS metrics is useful for short-term profitability. Critics also term them as unreliable since they are ever-changing. Experts like Larry Fink advice on the focus long-term goals. This ensures companies eventually find ways to strengthen their position in the stock market.

 

Jeremy Goldstein argues that both means can be beneficial to investors and employees. EPS offer mild incentives hence boosting work morale. As a remedy to its downside Executives should be held accountable for their actions. This can also be done by ensuring that pay per performance is measured against long-term goals. This will enable a steady growth rate for the company’s share price.

 

About Jeremy Goldstein.

 

Jeremy L. Goldstein is an attorney in New York City. He is a senior partner at his recently founded firm Jeremy L. Goldstein & Associates LLC. It is a boutique law firm dedicated to advising corporations on executive compensation and corporate governance matters. Before founding his firm, he was a partner at Wachtell, Lipton, Rosen & Kaltz. He has also worked with several other companies. Such as; cellular companies, oil and petroleum companies, stockholder companies and banking companies. His work for them was in matters of monetary legality and compensation. He has also written several books and journals providing counsel on current and popular legal matters.

 

In the Legal 500, Jeremy Goldstein has been listed as top selections for legal counsel. He is a member of American bus association (business section). He is the chairperson of the Mergers and Acquisitions Committee.

Jason Hope Commits to Anti-Aging Research in Philanthropic Outreach.

We are living in the fascinating world of nearly constant technological innovation. In order for this change to constantly be occurring, there need to be leaders making prominent decisions in order to help facilitate it. One of those leaders is Jason Hope, a renowned futurist, and an acclaimed philanthropist. Hope has become one of the foremost leaders in the discussion surrounding the Internet of Things, or IoT for short. The Internet of Things refers to the way by which all of our devices connect with one another in order to make our lives easier. Imagine a world completely dominated by smart technology and you are close to the mark. However, Hope isn’t solely focused on the IoT. He is also a firm believer in anti-aging technology. Anti-aging technology, Hope believes, is the future and a difference can be made sooner than later. In fact, Hope was so devout in his belief that he took his checkbook out in order to donate to the cause. Entrepreneur Jason Hope Invests in Research Against Aging

Jason Hope was born in Tempe, AZ and he went on to study finance at Arizona State University. Hope would breeze through his MBA before setting his sights on technology. Throughout the years, Hope has primarily been focused on his futurism but he hasn’t lost sight of his passions — and one of those passions is the pursuit of anti-aging technology. In order to double-down and prove his support of the tech, Hope would sign a $500,000 donation to the vaunted SENS Foundation.  Understanding the Internet-of-Things Revolution: A quick guide for thriving in the IoT era

The SENS Foundation is a non-profit out of California that focuses on developing solutions to some of the fundamental questions surrounding why humanity ages. Hope found the SENS Foundation to be one of the most prolific operators in the field and he knew right away that he had to be a part of what they are doing. Hope touted the work of Dr. Aubrey de Grey before saying that his work was ‘essential’ in the pursuit of medication that helps to fight age-related illness, such a Diabetes and Alzheimer’s. Jason Hope’s Hard Line Stance on the Internet of Things

Hope’s donation to the non-profit was announced at a charity event hosted by Peter Thiel of the Thiel Foundation. Thiel himself spoke highly of Hope’s donation, claiming that it was a ‘bold commitment’ to the future of anti-aging research. Dr. Aubrey De Grey was also in attendance and he was able to point specifically to where Hope’s donation would go in the research process: the study of arteriosclerosis which is the hardening of our arteries and a source of hypertension when we grow older. Jason Hope Pledges $500,000

How Talkspace is Changing Lives

The ability to go and see a therapist is one of the most important things that you can do for your mental health and well-being. A lot of people forgo seeing a therapist because of the inconvenience and cost that is involved. For example, if you do not have any type of health insurance, you might find that it costs you hundreds of dollars just to be able to go and see a therapist each and every week. This is something that many people simply cannot afford, and it is why a New York City company created a wonderful service known as Talkspace.

Talkspace has revolutionized the world of therapy for so many people, as it allows you to easily and quickly message your therapist using a mobile device. This takes the guesswork out of getting in contact with someone professional who is both licensed and experienced with what you are dealing with at the moment. You will find that working with a professional like this is one of the easiest things that you have ever done considering the fact that there are so many different options available to you.

In order for you to get started with Talkspace, you are going to want to download the app to your mobile device and create your very own account. Once you create your own account, you will be matched with a wonderful therapist who is experienced in the type of issues that you happen to be dealing with right now. You will then be able to message a therapist at virtually any time, as this is something that is going to help you to feel confident in the fact that you are finally getting the help that you need. Talkspace is ideal for all types of people, whether you are dealing with a mental health disorder or you just want somebody to talk to each and every day.

How The Financial Experts At Agora Financial Inform Investors

Many people want to invest their money in the stock market but they’re not sure how to go about it. They also want other financial advice such as how to protect their money from people and organizations who want to take it from them. Agora Financial, LLC, is a media company that publishes independent commentary in order to help people accomplish both of these goals.

Check out more Agroa Financial on their YouTube channel.

More and more people are becoming aware that most financial advisors are looking out for their own interests, not those of their clients. Therefore they want to make their own investments decisions but they need guidance on how best to do so. Agora Financial disburses information about investing in a number of ways. they have publications that are available in print and online, for example. They also produce films and hold conferences around the world that explain economics to people.
Beyond financial advisors, there are a number of other organizations who want to take your money from you when you decide to invest. This includes insurance companies, the federal and state governments, and bankers among others. To help with this Agora Financial informs people about how to protect their wealth and keep as much of it as they can.
Agora Financial has a team of financial experts. This includes those who are experts in natural resources. For example, they have a geologist on their staff who graduated from Harvard who has many years of experience investing in assets like mines and oil. They also have a billionaire and philanthropist who made his fortune on his own, as well as some of the best bond experts in the world. Additionally, one staff member has won the New York Times best selling author title no less than three times.

It was in 1979 that Agora Financial was founded by Bill Bonner. Members of this organization have appeared on many financial shows over the years such as those on CNBC, Fox Business News, and Bloomberg. They have many publications with some of the best known being Capital & Crisis, Daily Resource Hunter, Penny Sleuth, Strategic Short Report, and Technology Profits Confidential.
Each year this business holds an Agora Financial Investment Symposium. They have been doing this annual event in Vancouver, British Columbia, since 1999. Over the years they have had many keynote speakers who are experts when it comes to investing such as Steve Forbes, Nicholas Taleb, and Jim Rogers.

For more information follow Agora Financial on Facebook.

Luiz Carlos Trabuco Cappi Appointed To More Leadership At Bradesco Bank

Recently, there have been a lot of improvements to the way that leadership is maintained at Bradesco Bank. The institution has propagated a great deal of change in their industry based on the development of core leadership standards and selection decisions. As Lazaro Brandao has announced he will no longer be the President of the organization, a spiraling need for new leadership has emerged in the second largest bank of Brazil.

While Brandao will maintain leadership in the holding companies that are available, he does not have the same intention for maintaining his position in the office of the President. He has created a lot of change and implemented great standards throughout his career, and now feels the need to step down. This announcement has come with a great degree of support from his family as Brandao is now ninety one years of age.

Because of this decision, a new President has been appointed. This is the current CEO, Luiz Carlos Trabuco Cappi. He has been an empowering individual to hold office and has propagated a great deal of change throughout the institution. Nevertheless, it is not possible for one individual to hold both offices of CEO and President. For this reason it has become even more important that a CEO is selected. A graduate of Sao Paolo University, he started to work as clerk.

Read more: Trabuco: Despite the uncertainties, investors believe in the country


The management culture that has been established at Bradesco Bank is very unique. They almost always select executives from within the organization when it comes to promotions and leadership positions. For this reason, there have been seven executive leaders selected for the candidacy of CEO. These individuals have proved themselves in various aspects including the steadfast development of resources in their unique areas of expertise.

Domingos Figueiredo Abreu is one of the candidates for this CEO position. He has been instrumental in changing the treasury department of the bank. He has also been a key figure in lending departments. With a steadfast history at the company it is clear that he has the successful attitude and history to make a difference as CEO. The treasury department in particular has been enhanced due to the novel implementation standards proposed by this officer.

There are several other notable figures in the running for this position as well including Josue Augusto Pancini. Josue Augusto Pancini is another candidate with a great track record. He has been instrumental in helping the bank branch out and has created steadfast results for local as well as international standards of implementation.

Marcelo de Araujo Noronha is another competent and highly skilled individual in the running for the office of CEO. He is a little younger than some of the other candidates as he is only fifty two years of age. He started working with the bank in 2003 and has made a big difference in the way that corporate investment as well as banking takes place at large scale. The card operations of Bradesco BBI have been implemented very effectively with the help of Noronha as well. This project speaks to the way that he is able to create valuable services and ensure that they are deployed correctly to the people they will serve best.

Another candidate is Octavio de Lazari according to infomoney.com.br. He is only fifty four years old and has been a member of upper level management for quite some time. He has one of the longest histories at the bank having been there since 1978. The valuable administration of projects in addition to the way that he addresses insurance trends has propagated a great deal of change throughout the infrastructure at large. There are valuable benefits that can be seen throughout the organization based on his consistent and steadfast efforts.

Find more about Luiz Carlos Trabuco Cappi: https://g1.globo.com/economia/negocios/noticia/sucessao-no-conselho-do-bradesco-foi-um-ato-planejado-diz-trabuco.ghtml

George Soros-His Fortune And His Philanthropy

George Soros, who was at one point the 19th richest person alive, has diminished his vast fortune immensely by donating $18 billion to the Open Society Foundations according to Forbes. The philanthropist has a long history of donating to philanthropy groups and other charities across the world. He has also made efforts to bring about political change in America, as well as in Central and Eastern Europe. Soros amassed his large fortune by banking and working for various companies both as a stock trader and as a hedge fund manager. He worked first fro Singer and Friedlander, a merchant bank in London. This was after his graduation from the London School of Economics.

Soros used his knowledge of economics, as well as his immense knowledge of philosophies to develop new techniques to predict and take advantage of shifts in the market. Soros first came to America in 1956 so that he could take a position as a European stock trader for F.M. Mayer. In 1959 he began working at Wertheim & Co. once again dealing in European securities and stocks.

In 1963Soros was asked to take up the position of vice president at Arnhold and S. Bleichroeder. He accepted and during his ten-year tenure he developed a number of funds, most prominently the Double Eagle hedge fund. This fund initially started with $4 million had developed to a value of $12 million by 1973. In 1970 Soros created Soros Fund Management. In 1973 he became chairman of this Management firm after leaving Arnhold and S. Bleichroeder.

In 1991 Soros was able to further expand his fortune by predicting a downfall in the value of the British Pound and shorting the market.
George Soros has long been involved in Philanthropy. In 1984 he created the Open Society Institute in Hungary. This organization would grow into the Open Society Foundations we know today.

Through the Open Society Foundations, Soros has been able to fund a variety of groups. He backed several dissidents against communism in Eastern and Central Europe, including the Solidary Movement in Poland. The Open Society Foundations also operate in Africa and are a major force in bringing about regime changes and peacefully implementing democratically elected governments throughout the continent. Soros also funds the Millennium Promise in Africa which, through better agricultural methods, education, and healthcare, hopes to end extreme poverty in the continent and around the world.

Soros’s recent $18 billion donations will ensure that these efforts are funded for many years, and will ensure that they can expand to other areas of the world that are in need.

To Read More : www.forbes.com/profile/george-soros/

Highland Capital Management Donates $10 Million for Bush Center

Highland Capital Management is a popular institution that was introduced into the market several years ago. The organization has been playing a vital role in supporting needy families based in Dallas and other parts of the country. The leadership of the company has been instrumental in the donations offered by the company. The New Year has started on a sound and prosperous note for some organizations thanks to Highland Capital Management. According to a report published by the George W Bush Presidential Center, Highland Capital Management will be giving a ten million dollar endowment gift in the New Year. The huge donation will mostly be used to support the public programs that have been initiated by the Bush Center. Visit highland.com to know more.

The Bush Center has announced that it is very excited about the new developments. According to top officials from the institution, Highland Capital Management will be the sole sponsor for a program series that is known as Engage at Bush Center. The program is a good way to bring together thoughtful leaders, authors, lecturers and newsmakers to the Bush Center for crucial discussions that will be held all through the year. The chief executive officer of the Bush Center, Hersh Kenneth says that the new funding will be a great start for the organization that has been in the market for some time now. Jim Dondero, the president and co-founder of the powerful institution has played a critical role in the new funding initiative.

Visit: http://www.investopedia.com/articles/investing/031216/highland-capital-management-investment-manager-highlight.asp

According to Kenneth Hersh, Highland Capital Management has been instrumental in making the Bush Center successful since it was established in the year 2012. The non-profit making organization has only been doing well due to the support it has been receiving from Jim and his team. Kenneth says that Jim Dondero has been very generous with the company resources, and he has transformed many lives based in Dallas. Jim has a great commitment to community initiatives, and this is why he has supported the Bush Center from the start.

The Dallas based investment company has had a significant share of challenges since it was founded many years ago. Despite these numerous problems, the organization has chosen to support worthy causes in the society, especially the programs for communities living in Dallas. As the co-founder of the successful international firm, Jim Dondero has proven to be a great leader, and he has done his best to ensure that the company is successful. Read more at Biz Journals about Highland Capital.

Oncotarget; using knowledge to defeat cancer

Oncotarget is a medical journal that concerns itself with publishing medical papers on oncology- the branch of medicine that deals with diagnosis, prevention and treatment of cancer. It publishes its papers twice a week and is published by impact journals.

Oncotarget’s main aim is to disseminate much needed information on oncology to doctors, patients and all who are affected by cancer. It stands out when compared to other informative journals because the editors have a way of simplifying information that normally medics only would understand, so that everyone who lays a hand on the paper understands easily. Download output styles at Endnote.com.

The editors, Mikhail Blagosklonny and Andrei V. Gudkov of Roswell Park Cancer Institute, have made sure that all paper published have not only the right and helpful information. This has given researchers and readers a like faith in their publications. Because of this, Octagon has been able to work with researchers to make ground breaking discoveries. Most recently, Dr. John R. Hawse from the department of biochemistry and molecular biology, mayo clinic in collaboration with Oncotarget published a paper on treatment of breast cancer. Learn more at researchgate.net

In the paper ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer, Dr. John explains that how drugs that stimulate the production of ERβ hormone might just be the cure to breast cancer we have all been waiting for. The doctor explains that patients who have ERα but lack ERβ are prone to cancer. But those who have ERβ respond to cancer treatments better and faster. So for the treatments to work, what needs to be done is stimulate the production of ERβ. https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&cad=rja&uact=8&ved=0ahUKEwjohNT4gdzYAhUHXhQKHZK_DYgQFggtMAE&url=https%3A%2F%2Fwww.eurekalert.org%2Fpub_releases%2F2017-12%2Frp-si111417.php&usg=AOvVaw23r0M4g67BuJPmKmaPL21C

Other than just working with researchers, Oncotarget tries to inspire, encourage and support the researchers they work with. Last year, Oncotrarget sponsored four researchers to the coveted Frontiers in cancer science 2017 which was held in Singapore. By funding the researchers travel and accommodation, Oncotarget enabled them to take the discussion on cancer even further. Holding discussions with likeminded scientists and researchers also helped the researchers get insights and inspiration they needed to take their work to the next level.

Information is power, they say. Oncotarget gets that. They know to win the war against cancer, they need to educate the masses.

Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/

Mike Baur Is Helping Usher In Great Change To Switzerland’s Entrepreneurship World

Mike Baur is the founder and Chairman of the Swiss Startup Factory, a new business investment company that helps entrepreneurs raise capital and provides temporary office space for them to grow their new companies without having to go through a lengthy process. There’s been a growing idea in Switzerland that the workforce has been too limited to traditional employment in institutions such as banking, and President Johann Schneider-Ammann gave the call for their to be more options and for investors to take more risks. The technology developing sector has been growing and Baur believes the time is now to answer the call to build it. That’s why he uses incentives such as pitch contests at seminars to help people understand what it takes to drive investment interest to a business.

 

Mike Baur once assumed that his career would begin and end in banking. He started at the age of 16 in an apprenticeship program, the way that many young Swiss men did at the time and started learning the ropes at UBS Bank. A human resources manager there even told him how he could get promoted and reach retirement if he followed a chart that was drawn up. Baur certainly caught on well to his job and by his mid 20s he was already earning promotions and even managing the investment funds of several prestigious clients. Things were looking good for about 17 years in this career until the US subprime mortage crisis of 2008 turned into an international banking crisis and UBS along other banks eventually had to shutter its doors.

 

Mike Baur stayed in banking for a few more years after leaving UBS and even earned an even higher management position at Clariden Leu. But he soon realized that the banking industry was going to continue to decline and it no longer became the way that he wanted to go to reach retirement. So Baur left banking in 2014 and looked into other investment ideas. He soon explored the tech entrepreneur world and realized that though many of these new business-minded individuals had great ideas and even plans to make things happen, they simply lacked the financial connections to do so. So Baur got the idea for the Swiss Startup Factory and after partnering with several capital firms, he brought the accelerator into full swing. It’s objective is to take its applicants through a 3-month program and prove to investors that their company can succeed against stiff competition.

 

Clay Siegall discovers way to radically improve effectiveness of cancer treatment

Over the course of the last 50 years, one of the main problems facing cancer researchers and oncologists has been the inability of the latter to administer high amounts of chemotherapeutic agents to any given patient. This is the direct result of the fact that chemotherapy is, by definition, lethal poison, designed to kill all cells with which it comes into direct contact. Unfortunately, this property has led it to become one of the most side-effect-inducing drugs currently in existence, severely limiting the amount of the drug that can be administered at any given time.

This has proven to be a serious constraint on the effectiveness of traditional chemotherapy. Throughout the late 1980s and early 1990s, many cancer researchers began focusing in on a class of treatments known as targeted cancer therapies. The idea behind this broad category of drugs was to allow for the direct targeting of malignant tissue, thereby dramatically reducing side effects as well as increasing the amount of the drug that can be administered to a patient at a given time.

No one has been more instrumental in the creation of these new types of drugs than Clay Siegall. After having first spent four years as a researcher at the National Cancer Institute, one of the most prestigious cancer research institutions in the world, Dr. Siegall then was recruited by Bristol-Myers Squibb, one of the largest pharmaceutical companies in America. While there, Dr. Siegall began working on a new type of targeted cancer therapy known as antibody drug conjugates. These drugs use synthetic human antibodies as a means to deliver highly lethal cytotoxins directly to the site of malignant tumors. At least in theory, such drugs would be capable of completely eliminating the side effects of most patients experienced while undergoing chemotherapy.

Dr. Siegall then went on to found his own company, Seattle Genetics, which is the only biotech company in the world focusing solely on the creation of antibody drug conjugates. By 2011, Seattle Genetics had achieved its first FDA-approved antibody drug conjugate, called ADCetris. Today, this drug saves thousands of lives every single year.